Physiomics Share Price | |
---|---|
Price | 1.35 |
Bid | 1.30 |
Ask | 1.40 |
Change | 0.05 (3.85%) |
Volume | 685,007 |
Open | 1.30 |
High | 1.35 |
Low | 1.30 |
Prev. Close | 1.35 |
Currency | GBX |
---|---|
Issue Country | GB |
Shares in Issue | 135.47m |
Market Capitalisation | £1.83m |
Market Size | 75,000 |
52 Week High | 3.15 |
52 Week High Date | 10-May-2023 |
52 Week Low | 0.925 |
52 Week Low Date | 09-Aug-2023 |
# Trades | 18 |
---|---|
Vol. Sold | 2,183 |
Sold Value | £N/A |
Vol. Bought | 682,824 |
Bought Value | £9.37k |
PE Ratio | -2.755102 |
Earnings | -0.49 |
Dividend | 0.00 |
Yield | 0.00% |
Date | Time | Trade Prc | Volume | Buy/Sell | Bid | Ask | Value | |
---|---|---|---|---|---|---|---|---|
07-May-24 | 16:23:36 | 1.305 | 80 | Sell* | 1.30 | 1.40 | 1.04 | O Ordinary |
07-May-24 | 16:22:15 | 1.305 | 1,500 | Sell* | 1.30 | 1.40 | 19.58 | O Ordinary |
07-May-24 | 15:53:19 | 1.40 | 35,714 | Buy* | 1.30 | 1.40 | 500.00 | O Ordinary |
07-May-24 | 15:51:34 | 1.40 | 1,858 | Buy* | 1.30 | 1.40 | 26.01 | O Ordinary |
07-May-24 | 15:02:47 | 1.394 | 35,582 | Buy* | 1.30 | 1.40 | 496.01 | O Ordinary |
07-May-24 | 13:59:12 | 1.394 | 3,741 | Buy* | 1.30 | 1.40 | 52.15 | O Ordinary |
07-May-24 | 13:39:22 | 1.375 | 27,500 | Buy* | 1.30 | 1.40 | 378.13 | O Ordinary |
07-May-24 | 13:31:59 | 1.40 | 111,555 | Buy* | 1.30 | 1.40 | 1,562 | O Ordinary |
07-May-24 | 13:14:29 | 1.38 | 70,000 | Buy* | 1.20 | 1.40 | 966.00 | O Ordinary |
07-May-24 | 13:13:26 | 1.364 | 90,000 | Buy* | 1.20 | 1.40 | 1,228 | O Ordinary |
Announced | Traded | Action | Notifier | Price | Currency | Amount | Holding |
---|---|---|---|---|---|---|---|
25-Jul-23 | 22-Jul-23 | Transfer To | James Simon Millen held the position of Executive Chairman at the time of this trade.James Simon Millen | 0.00 | 500,000 | 1,884,393 | |
18-Jul-23 | 14-Jul-23 | Transfer To | Christophe Chassagnole held the position of COO at the time of this trade.Christophe Chassagnole | 0.00 | 500,000 | 1,102,723 | |
29-Jun-21 | 28-Jun-21 | Transfer To | Christophe Chassagnole held the position of COO at the time of this trade.Christophe Chassagnole | 0.00 | 85,715 | 602,723 | |
21-May-21 | 21-May-21 | Transfer To | James Simon Millen held the position of CEO at the time of this trade.James Simon Millen | 0.00 | 242,287 | 1,384,393 | |
22-Mar-21 | 29-Jan-21 | Transfer To | James Simon Millen held the position of CEO at the time of this trade.James Simon Millen | 0.00 | 242,287 | 1,384,393 |
Physiomics is a leading oncology drug development consultancy using proprietary state of the artVirtual Tumour™ technology and other tools to predict and better understand the effects of cancer treatments. We work with partners developing cancer drugs to help them save time and money during pre-clinical and clinical development.